Michael Demeure, MD
Surgery · Newport Beach, CANPI 1629041579
Payments from drug & device makers
Across 216 payments — averaging $7667.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aadi Bioscience, Inc.$1.3M
- Otsuka Pharmaceutical Co., Ltd.$162K
- Mirati Therapeutics, Inc.$62K
- Taiho Oncology, Inc.$47K
- Eli Lilly$27K
- Exelixis Inc.$26K
- plus $31K from 12 others
What the payments were for
- Consulting fees$36,61069%
- Speaking & faculty fees$11,65822%
- Travel & lodging$2,8405%
- Food & beverage$1,6203%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aadi Bioscience, Inc. | 134 | $1,302,247 |
| Otsuka Pharmaceutical Co., Ltd. | 9 | $161,726 |
| Mirati Therapeutics, Inc. | 8 | $61,836 |
| Taiho Oncology, Inc. | 7 | $47,185 |
| Eli Lilly | 7 | $26,950 |
| Exelixis Inc. | 16 | $25,809 |
| Bayer | 10 | $13,875 |
| Corcept Therapeutics | 14 | $8,946 |
| Array Biopharma Inc | 1 | $4,200 |
| Boehringer Ingelheim | 1 | $3,060 |
| Covidien LP | 2 | $162 |
| Roche Diagnostics Corporation | 1 | $136 |
| Baxter Healthcare | 1 | $36 |
| Acell, Inc. | 1 | $31 |
| Foundation Medicine, Inc. | 1 | $28 |
| AbbVie | 1 | $17 |
| Caris MPI, Inc. | 1 | $16 |
| Integra Lifesciences Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,656,273 in reported general payments places this provider in the 95th percentile of 2,363 surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 65 | $544 |
| Oxycodone Hcl | 21 | $34 |
Paid to pharmacies, not to this prescriber.
Other surgery in Newport Beach
- Timothy ChuterSan Francisco$8.9M
- Peter StockSan Francisco$6.5M
- Santiago HorganSan Diego$2.8M
- Kenneth DeckLaguna Hills$2.4M
- Daniel RiskinSan Jose$2.2M
- Rock LiuHayward$1.6M
- David LouriePasadena$1.4M
- Andrea PakulaThousand Oaks$1.4M
- Siew-Ming LeeFresno$1.3M
- Beemen KhalilPalo Alto$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.